News

The company has posted a net income of $673,000 for the second quarter of 2011, compared to $1.35m for the same period in 2010. The company’s operating income

Volini Duo, which is developed using advanced Matrix technology, is a bi-layered Acetaminophen tablet, specially formulated to give dual pain relief. Matrix technology allows the regulated release of

The trial is being organized in Australia, Canada, France, the UK and the US under a special protocol assessment (SPA) granted by the US Food and Drug Administration

As per the terms of the agreement, CHDI will fund Isis to identify and conduct IND-enabling studies on an antisense drug targeting the huntingtin gene. Additionally, Isis is

Transgenomic’s net loss was $6m, compared to $1.15m for the same period in the prior year. The company’s loss from operations was $1.62m for the second quarter ended

Mylan‘s Alfuzosin Hydrochloride Extended-release Tablets, 10mg are generic equivalent to Uroxatral, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Uroxatral belongs to a group

Avanir alleged that Par’s and Actavis’ proposed generic products infringe certain patents held by the company. The law suit was filed based on the response to abbreviated new

ChromaDex’s net loss was $1.84m, compared to $303,529 for the same period in the prior year. The company’s operating loss was $1.83m for the second quarter ended July

Earlier, the FDA had requested the company to organize two clinical trials – in patients with type 1 diabetes and type 2 diabetes, with the company’s next-generation inhaler.